Drug · CHEMBL563

FLURBIPROFEN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. FLURBIPROFEN. Drugs and targets, record CHEMBL563. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL563

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: FLURBIPROFEN; ChEMBL
ChEMBL ID: CHEMBL563; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Ansaid, Cebutid, Froben, Froben sr, Strefen, Transact; ChEMBL
Other names: BTS 18,322, BTS-18322, Flubiprofen, Flurbiprofene, Flurbiprofeno, NSC-757037, U-27,182, U-27182; ChEMBL
Other form: FLURBIPROFEN SODIUM, CHEMBL3989754; Drugs and targets
DrugBank: DB00712; DrugBank
InChIKey: SYTBZMRGLBWNTM-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 6 of its 16 diseases, from ATC, DailyMed and TTD; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
PTGS1	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5742
PTGS2	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5743

Source ChEMBL

Diseases16

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
Low back pain	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0003419
periodontitis	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005076
pharyngitis	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0002258
Cough	Early phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0012735
Hoarse voice	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0001609
Pain	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0012531
Recurrent upper respiratory tract infections	Early phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0002788
acute myeloid leukemia	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0018874
post operative nausea and vomiting	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_0004888
type 2 diabetes mellitus	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005148

1 to 10 of 16Source Open Targets

See all 16 diseases

Trials62

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 16 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01049334	A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis	Phase 3	204	2017-09-21	flurbiprofen	Its name	ClinicalTrials.gov
NCT01048866	A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis	Phase 3	198	2017-09-21	flurbiprofen	Its name	ClinicalTrials.gov
NCT02043366	Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients		180	2015-09-28	flurbiprofen axetil	Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers	ClinicalTrials.gov
NCT00759330	Flurbiprofen Tape for Treatment of Chronic Low Back Pain	Phase 2	127	2016-10-06	flurbiprofen	Its name	ClinicalTrials.gov
NCT01986361	Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method	Phase 3	122	2017-08-24	flurbiprofen	Its name	ClinicalTrials.gov
NCT05981365	Voxelotor CYP and Transporter Cocktail Interaction Study	Phase 1	44	2024-11-22	flurbiprofen	Its name	ClinicalTrials.gov
NCT05368831	Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects	Phase 1	24	2024-03-08	flurbiprofen	Its name	ClinicalTrials.gov
NCT04425902	Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults	Phase 1	20	2022-05-23	flurbiprofen	Its name	ClinicalTrials.gov
NCT07370402	The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster		750		flurbiprofen	Its name	ClinicalTrials.gov
NCT02789527	Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations		367		flurbiprofen	Its name	ClinicalTrials.gov

1 to 10 of 62

See all 62 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge: serious adverse events	0 of 102	0 of 102	204	NCT01049334	Trial comparisons
Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge: serious adverse events	0 of 101	0 of 97	198	NCT01048866	Trial comparisons
Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge: serious adverse events	0 of 101	0 of 21	122	NCT01986361	Trial comparisons
Part A: Period 1 vs Part A: Period 2: Part A: Number of Participants With Clinically Significant Abnormalities in Vital Signs	0 of 26	1 of 25	51	NCT05981365	Trial comparisons
Part A: Period 1 vs Part A: Period 2: Part A: Number of Participants With Clinically Significant Abnormalities in Laboratory Tests	0 of 26	0 of 25	51	NCT05981365	Trial comparisons
Part A: Period 1 vs Part A: Period 2: Part A: Number of Participants With Clinically Significant Abnormalities in Physical Examinations	1 of 26	0 of 25	51	NCT05981365	Trial comparisons
Part B: Period 1 vs Part B: Period 2: Part B: Number of Participants With Clinically Significant Abnormalities in Vital Signs	0 of 18	0 of 18	36	NCT05981365	Trial comparisons
Part B: Period 1 vs Part B: Period 2: Part B: Number of Participants With Clinically Significant Abnormalities in Physical Examinations	0 of 18	0 of 18	36	NCT05981365	Trial comparisons
Part B: Period 1 vs Part B: Period 2: Part B: Number of Participants With Clinically Significant Abnormalities in Laboratory Tests	0 of 18	0 of 18	36	NCT05981365	Trial comparisons

Papers from its trials11

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37800597	DERIVED	1	PubMed
37328712	DERIVED	1	PubMed
35570253	DERIVED	1	PubMed
32851583	DERIVED	1	PubMed
30007054	DERIVED	1	PubMed
29381110	DERIVED	1	PubMed
27146963	DERIVED	1	PubMed
25296661	DERIVED	2	PubMed
24988909	DERIVED	1	PubMed
24722393	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL563

GET https://conductscience.org/api/drugs/v1/CHEMBL563/trials?page=2

API reference For AI assistants